drugset / Trial / NCT07114406

A Study to Evaluate Safety and Efficacy of PBK_M2502

NCT07114406 ↗

Phase 3 Not yet recruiting 110 enrolled Pharmbio Korea Co., Ltd.
RandomizedParallel-groupSingle-blindDiagnostic

Summary

This clinical trial was prospective, randomized, single-blind, 3-treatment arm, parallel treatment group, and active-controlled. , Multi-center, Phase 3 confirmatory clinical trial.

Timeline

Start
2025-08
Primary completion
2026-08
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PBK_M2502 Unknown — —

Indications